154 related articles for article (PubMed ID: 25650090)
1. Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
Chen X; Newell LF; Xie H; Walter RB; Pagel JM; Sandhu VK; Becker PS; Hendrie PC; Abkowitz JL; Appelbaum FR; Estey EH
Leukemia; 2015 Aug; 29(8):1779-80. PubMed ID: 25650090
[No Abstract] [Full Text] [Related]
2. Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.
Kannan KK; Vellanki P; Isom S; Tawfik B; Winter A; Klepin HD; Ellis LR; Bhave RR; Howard D; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
Leuk Res; 2021 Dec; 111():106731. PubMed ID: 34695644
[No Abstract] [Full Text] [Related]
3. [A case of acute myelogenous leukemia accompanied with myelofibrosis and megakaryocyte-like giant bizarre blasts].
Yasunaga M; Hodohara K; Bamba F; Kitamura K; Fukuda M; Boku T; Miyagawa A; Inoue T; Kitoh K; Andoh A
Rinsho Byori; 1995 Oct; 43(10):1078-82. PubMed ID: 8531394
[TBL] [Abstract][Full Text] [Related]
4. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.
Lacombe F; Arnoulet C; Maynadié M; Lippert E; Luquet I; Pigneux A; Vey N; Casasnovas O; Witz F; Béné MC
Leukemia; 2009 Feb; 23(2):350-7. PubMed ID: 18987664
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia.
Dengler R; Plewan A; Münstermann U; Busch R; Eger G; Emmerich B
Clin Cancer Res; 1995 Feb; 1(2):199-205. PubMed ID: 9815974
[TBL] [Abstract][Full Text] [Related]
6. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
[TBL] [Abstract][Full Text] [Related]
9. Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Gianfaldoni G; Mannelli F; Baccini M; Antonioli E; Leoni F; Bosi A
Br J Haematol; 2006 Jul; 134(1):54-7. PubMed ID: 16803567
[TBL] [Abstract][Full Text] [Related]
10. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H; Seymour JF; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Bernal del Castillo T; Al-Ali HK; Martinelli G; Falantes J; Noppeney R; Stone RM; Minden MD; McIntyre H; Songer S; Lucy LM; Beach CL; Döhner H
Blood; 2015 Jul; 126(3):291-9. PubMed ID: 25987659
[TBL] [Abstract][Full Text] [Related]
11. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
12. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
[TBL] [Abstract][Full Text] [Related]
13. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
14. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
[TBL] [Abstract][Full Text] [Related]
15. Clonality switch in acute myeloid leukemia.
Yin JA; Jowitt SN
Leuk Lymphoma; 1996 Jun; 22(1-2):125-30. PubMed ID: 8724539
[TBL] [Abstract][Full Text] [Related]
16. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study.
Franchi A; Papa G; D'Atri S; Piccioni D; Masi M; Bonmassar E
Haematologica; 1992; 77(2):146-50. PubMed ID: 1398299
[TBL] [Abstract][Full Text] [Related]
18. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
19. Major response of PNH to an AML chemotherapy protocol.
Füreder W; Sperr WR; Gleixner K; Thalhammer R; Schwarzinger I; Hoermann G; Kornauth C; Grünberger B; Valent P
Ann Hematol; 2018 Aug; 97(8):1487-1488. PubMed ID: 29568989
[No Abstract] [Full Text] [Related]
20. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome.
Herst PM; Howman RA; Neeson PJ; Berridge MV; Ritchie DS
J Leukoc Biol; 2011 Jan; 89(1):51-5. PubMed ID: 20959411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
